Andrieu has received grants from Servier and Chiesi; has performed lectures for Beaufour Novartis and Chiesi; and has received fees for participation in review activities for Cure Huntington's Disease foundation. Prof. Vellas has received grants from BMS, and Wyeth, and is board member of Eisai and Astra. All other authors declare that they have no conflict of interest ,
Memantine for dementia, Cochrane Database Syst Rev, vol.50, issue.8, p.3154, 2006. ,
DOI : 10.1002/14651858.CD003154.pub5
Cholinesterase inhibitors for Alzheimer's disease, Cochrane Database Syst Rev, vol.11, issue.suppl 2, p.5593, 2006. ,
DOI : 10.1002/14651858.CD005593
Chronic Donepezil Treatment Is Associated with Slowed Cognitive Decline in Alzheimer???s Disease, Dementia and Geriatric Cognitive Disorders, vol.12, issue.4, pp.295-300, 2001. ,
DOI : 10.1159/000051272
Long-term efficacy and safety of donepezil in the treatment of Alzheimer???s disease: final analysis of a US multicentre open-label study, European Neuropsychopharmacology, vol.10, issue.3, pp.195-203, 2000. ,
DOI : 10.1016/S0924-977X(00)00067-5
Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease, International Journal of Geriatric Psychiatry, vol.57, issue.230, pp.806-818, 2007. ,
DOI : 10.1002/gps.1746
Effect of discontinuing cholinesterase inhibitor therapy on behavioral and mood symptoms in nursing home patients with dementia, The American Journal of Geriatric Pharmacotherapy, vol.7, issue.2, pp.74-83, 2009. ,
DOI : 10.1016/j.amjopharm.2009.04.002
Comparison of persistence rates of acetylcholine-esterase inhibitors in a state Medicaid program, Patient Preference and Adherence, vol.2, pp.79-85, 2008. ,
DOI : 10.2147/PPA.S2652
A population-based study of dosing and persistence with anti-dementia medications, European Journal of Clinical Pharmacology, vol.76, issue.17, pp.1467-75, 2013. ,
DOI : 10.1007/s00228-013-1483-y
Anticholinesterase Duration in the Australian Veteran Population, Australian & New Zealand Journal of Psychiatry, vol.16, issue.5, pp.469-74, 2010. ,
DOI : 10.3109/00048670903555104
Persistence with Cholinesterase Inhibitor Therapy for Dementia, Drugs & Aging, vol.3, issue.5, pp.403-410, 2009. ,
DOI : 10.2165/00002512-200926050-00004
A Population-Based Study of Cholinesterase Inhibitor Use for Dementia, Journal of the American Geriatrics Society, vol.330, issue.(1, pp.1517-1540, 2007. ,
DOI : 10.1111/j.1532-5415.2007.01377.x
Decreased Persistence to Cholinesterase Inhibitor Therapy with Concomitant Use of Drugs That Can Impair Cognition, Pharmacotherapy, vol.56, issue.12, pp.1729-1764, 2005. ,
DOI : 10.1097/00002093-200201000-00008
Discontinuation of Cholinesterase Inhibitor Treatment and Determinants thereof in the Netherlands, Drugs & Aging, vol.25, issue.12, pp.663-75, 2010. ,
DOI : 10.2165/11538230-000000000-00000
Adherence, persistence and continuation with cholinesterase inhibitors in Alzheimer's disease, Australasian Journal on Ageing, vol.24, issue.1, pp.164-173, 2012. ,
DOI : 10.1111/j.1741-6612.2011.00564.x
Switching cholinesterase inhibitors in older adults with dementia, International Psychogeriatrics, vol.14, issue.03, pp.372-380, 2011. ,
DOI : 10.2165/00002512-200623100-00006
Comparison of Cholinesterase Inhibitor Utilization Patterns and Associated Health Care Costs in Alzheimer's Disease, Journal of Managed Care Pharmacy, vol.14, issue.5, pp.451-61, 2008. ,
DOI : 10.18553/jmcp.2008.14.5.451
Factors associated with persistence of cholinesterase inhibitor treatments in the elderly, Pharmacoepidemiology and Drug Safety, vol.21, issue.S146, pp.680-686, 2010. ,
DOI : 10.1002/pds.1933
TREATMENT PERSISTENCY WITH RIVASTIGMINE AND DONEPEZIL IN A LARGE STATE MEDICAID PROGRAM, Journal of the American Geriatrics Society, vol.37, issue.7, pp.1269-70, 2005. ,
DOI : 10.1111/j.1532-5415.2005.53384_9.x
PNL5 DRUG PERSISTENCY OF TWO CHOLINESTERASE INHIBITORS???RIVASTIGMINE VERSUS DONEPEZIL AMONG ELDERLY PATIENTS WITH ALZHEIMER'S DISEASE, Value in Health, vol.8, issue.3, pp.695-707, 2005. ,
DOI : 10.1016/S1098-3015(10)62819-7
How long can patients with mild or moderate Alzheimer???s dementia maintain both the cognition and the therapy of cholinesterase inhibitors: a national population-based study, European Journal of Neurology, vol.57, issue.3, pp.278-83, 2008. ,
DOI : 10.1159/000064929
Drug Persistency Patterns for Patients Treated With Rivastigmine or Donepezil in Usual Care Settings, Journal of Managed Care Pharmacy, vol.11, issue.3, pp.231-51, 2005. ,
DOI : 10.18553/jmcp.2005.11.3.231
Discontinuation of rivastigmine in routine clinical practice, International Journal of Geriatric Psychiatry, vol.17, issue.12, pp.1167-71, 2005. ,
DOI : 10.1002/gps.1411
Predictive Factors of Discontinuation and Switch of Cholinesterase Inhibitors in Community-Dwelling Patients with Alzheimer??s Disease, CNS Drugs, vol.25, issue.10, pp.431-473, 2010. ,
DOI : 10.2165/11318010-000000000-00000
Discontinuation of donepezil for the treatment of Alzheimer's disease in geriatric practice, International Psychogeriatrics, vol.25, issue.04, pp.800-806, 2008. ,
DOI : 10.1002/gps.1411
Conclusions:, The Canadian Journal of Neurological Sciences, vol.25, issue.05, pp.684-90, 2013. ,
DOI : 10.1002/pds.1933
Medication Adherence in Patients With Dementia, Alzheimer Disease & Associated Disorders, vol.28, issue.2, 2013. ,
DOI : 10.1097/WAD.0000000000000006
Patterns of cholinesterase-inhibitor use in the nursing home setting: A retrospective analysis, The American Journal of Geriatric Pharmacotherapy, vol.4, issue.2, pp.154-60, 2006. ,
DOI : 10.1016/j.amjopharm.2006.06.002
The ICTUS Study: A Prospective Longitudinal Observational Study of 1,380 AD Patients in Europe, Neuroepidemiology, vol.29, issue.1-2, pp.29-38, 2007. ,
DOI : 10.1159/000108915
Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease, Neurology, vol.34, issue.7, pp.939-983, 1984. ,
DOI : 10.1212/WNL.34.7.939
???Mini-mental state???, Journal of Psychiatric Research, vol.12, issue.3, pp.189-98, 1975. ,
DOI : 10.1016/0022-3956(75)90026-6
A new clinical scale for the staging of dementia, The British Journal of Psychiatry, vol.140, issue.6, pp.566-72, 1982. ,
DOI : 10.1192/bjp.140.6.566
Studies of Illness in the Aged, JAMA, vol.185, issue.12, pp.914-923, 1963. ,
DOI : 10.1001/jama.1963.03060120024016
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia, Neurology, vol.44, issue.12, pp.2308-2322, 1994. ,
DOI : 10.1212/WNL.44.12.2308
Relatives of the Impaired Elderly: Correlates of Feelings of Burden, The Gerontologist, vol.20, issue.6, pp.649-55, 1980. ,
DOI : 10.1093/geront/20.6.649
Persistence of Cholinesterase Inhibitor Treatment in Dementia: Insights from a Naturalistic Study, Dementia and Geriatric Cognitive Disorders Extra, vol.3, issue.1, pp.48-59, 2013. ,
DOI : 10.1159/000345279
Potential bias in pharmacoepidemiological studies due to the length of the drug free period: a study on antidepressant drug use in adults in the Netherlands, Pharmacoepidemiology and Drug Safety, vol.90, issue.5, pp.338-381, 2006. ,
DOI : 10.1002/pds.1223
Discontinuing cholinesterase inhibitors: results of a survey of Canadian dementia experts, International Psychogeriatrics, vol.9, issue.04, pp.539-584, 2011. ,
DOI : 10.1001/archneur.61.2.252
Pharmacological Treatment of Neuropsychiatric Symptoms of Dementia, JAMA, vol.293, issue.5, pp.596-608, 2005. ,
DOI : 10.1001/jama.293.5.596
When do we discontinue anti-dementia drugs? Views expressed by clinicians in a national survey within the United Kingdom, International Psychogeriatrics, vol.25, issue.09, pp.1-2, 2013. ,
DOI : 10.1056/NEJMoa1106668
Alarming arbitrariness in EU prescription and reimbursement criteria for anti-dementia drugs, International Journal of Geriatric Psychiatry, vol.330, issue.1, pp.29-31, 2006. ,
DOI : 10.1002/gps.1493
Which behavioral and psychological symptoms of dementia are the most problematic? Variability by prevalence, intensity, distress ratings, and associations with caregiver depressive symptoms, International Journal of Geriatric Psychiatry, vol.52, issue.1 ,
DOI : 10.1002/gps.4002
Compliance assessment of ambulatory Alzheimer patients to aid therapeutic decisions by healthcare professionals, BMC Health Services Research, vol.1, issue.1, p.232, 2010. ,
DOI : 10.1097/00045391-199412000-00003